How do you decide between injectables and energy-based treatments?
How do you decide between injectables and energy-based treatments? Start by mapping your exact symptoms and making sure foundations are in place (vaginal moisturiser, a suitable lubricant, and—when acceptable—local vaginal oestrogen or DHEA). Energy devices (laser/radiofrequency) mainly aim to remodel tissue; injectables (PRP or polynucleotides) try to condition superficial layers and improve slip at the entrance. Choice depends on symptom location, tolerance, contraindications and response to basics. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How do you decide between injectables and energy-based treatments? The best choice follows a step-wise pathway for genitourinary syndrome of menopause (GSM, sometimes called vaginal atrophy). First, confirm that symptoms truly reflect GSM rather than infection or a dermatosis; then build foundations: a scheduled vaginal moisturiser (many prefer hyaluronic acid gels) 2–4 times weekly and a compatible personal lubricant—water-based for versatility/condom use, silicone-based for long glide when the vestibule is tender, or oil-based for a rich feel (not latex-safe). If dryness, dyspareunia or urinary urgency/frequency still affect life, add local vaginal oestrogen or consider vaginal DHEA. Only when these are optimised should you weigh devices or injectables.
What devices aim to do. Energy-based treatments—fractional CO2/Er:YAG lasers or radiofrequency—deliver controlled warmth to the vaginal lining and submucosa to nudge repair, blood flow and collagen remodelling. When they help, people often report day-to-day movement feeling less “sandpapery”, fewer micro-tears at the posterior fourchette, and easier initial penetration. They do not replace hormonal biology; they mainly improve mechanical resilience. Sessions are typically brief, spaced 4–8 weeks apart, with short-lived warmth/spotting possible. Device-specific exclusions (e.g., certain implants for RF) and recent pelvic surgery without clearance mean some people should defer.
What injectables aim to do. Platelet-rich plasma (PRP) concentrates your own platelets and growth factors to encourage local repair and blood flow; polynucleotides (highly purified DNA fragments) are biostimulatory and water-binding, used to condition superficial tissue and improve slip. These are typically targeted to the vestibule (entrance) and/or vaginal wall in small aliquots with numbing. When they help, the “paper-cut” sting and friction at the entrance settle over weeks. Responses vary; short, spaced series (often 2–3 sessions) with reassessment are common. Severe fish allergy often excludes salmon-derived polynucleotides.
How to choose in real life. Match the tool to the dominant problem:
• Entrance-focused burning, splits or dyspareunia despite foundations and local therapy → consider injectables targeted to the vestibule to improve surface slip, and review placement of local oestrogen/DHEA (a fingertip to the vestibule can be crucial).
• Generalised vaginal dryness with canal discomfort on movement/speculum and thin epithelium despite local therapy → consider energy devices to support tissue remodelling, while continuing moisturiser + lubricant.
• Mixed symptoms → either option can be reasonable; choose the one that best addresses your main limiter first, then reassess.
When to avoid escalation. Post-menopausal bleeding, malodorous green/grey discharge, intense itch with thick white discharge, fever, visible blood in urine, new ulcers or rapidly changing white plaques all require assessment before any procedure. If pelvic floor guarding (protective muscle clench) is prominent after painful experiences, begin with pelvic health physiotherapy and, where useful, graded dilators; neither devices nor injectables relax muscles.
Sequencing and expectations. Whichever route you pick, build in pauses so you can judge effect: improvements are usually gradual over weeks, not immediate. Benefits are not permanent and often soften over months, so plan reviews at 6–12 weeks and again at 3–6 months to decide on maintenance. For a plain-English overview of how treatment steps are sequenced and why certain choices help, see treatment benefits.
Clinical Context
Who may lean towards injectables? People with vestibular stinging or “paper-cut” micro-tears that persist despite a disciplined moisturiser routine, generous silicone-based lubricant and well-placed local oestrogen/DHEA. Targeted superficial placement can reduce focal friction at the entrance.
Who may lean towards energy devices? Those with generalised canal dryness/irritation, speculum intolerance, or cycling/walking friction despite foundations and local therapy—provided there are no device-specific contraindications. Expect short-lived warmth/spotting; space sessions 4–8 weeks apart.
Alternatives and next steps. Maintain gentle external care (lukewarm water; bland emollient as a soap substitute), choose breathable underwear, avoid fragranced products, and review bike saddle/kit if friction triggers flares. If progress stalls after two sessions of any modality, pause and reassess diagnosis and placement before repeating. Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Foundations first (UK): Patient-friendly advice on symptoms, self-care and red flags appears on the NHS page for vaginal dryness. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local options can be used with or without HRT.
Comparators with robust evidence: Systematic reviews in the Cochrane Library show that local vaginal oestrogens improve dryness, soreness, dyspareunia and pH versus placebo across creams, tablets/pessaries and rings—providing the benchmark for symptom relief and maintenance.
Device oversight: UK expectations for intended use, marking, vigilance and safety reporting for medical devices are set by the national regulator; see the MHRA medical devices pages.
Pathophysiology & emerging options: Peer-reviewed overviews indexed on PubMed describe GSM biology (thinner epithelium, raised pH, reduced lactobacilli) and why local therapies are foundational, with energy devices and injectables (PRP, polynucleotides) as evolving adjuncts with heterogeneous evidence.
Applying the evidence: Use a stepped plan—foundations → add local therapy if needed → consider devices or injectables when appropriate. Match option to symptom pattern, place treatments precisely (especially at the vestibule), and schedule reviews to aim for the lowest effective maintenance. ® belongs to its owner.